Since IRE1α and PERK can respond to therapy-induced stress by triggering pro-tumor proliferative signals or anti-tumor apoptotic signals, there is an unmet need for patient stratification and personalized biomarker development when incorporating UPR inhibitors into clinical workflows and treatment paradigms. Here, EIF2AK3 is linked to neoplasm.